1 / 56

DIABETES CONTROL

DIABETES CONTROL. The Alphabet Strategy. A dvice Smoking , diet , exercise B lood pressure < 140/80 C holesterol TC ≤ 4 , LDL : HDL ≤ 2 D iabetes control HbA1c ≤ 7% E ye examination Annual examination F eet examination Annual examination G uardian drugs Aspirin, ACEI, statins &c.

razi
Download Presentation

DIABETES CONTROL

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. DIABETES CONTROL

  2. The Alphabet Strategy • Advice Smoking , diet , exercise • Blood pressure < 140/80 • Cholesterol TC ≤ 4 , LDL : HDL ≤ 2 • Diabetes control HbA1c ≤ 7% • Eye examination Annual examination • Feet examination Annual examination • Guardian drugs Aspirin, ACEI, statins &c

  3. Effect on diabetes complications of HbA1c% reduction Reductions in HbA1c and corresponding reductions in microvascular and macrovascular complications described in major studies of persons with T1 DM and T2 DM

  4. UKPDS : HbA1c% 7.0% versus 7.9% endpoints Micro albuminuria any diabetes Retinal laser micro vasculars cataract MI 0% -5% -10% 12% 16% -15% -20% P=0.052 25% 24% -25% 29% P=0.046 P=0.0099 33% -30% P=0.0031 -35% P<0.001

  5. UKPDS : glycaemic control

  6. Type 1 diabetes - treatment options

  7. Type 1 diabetes - treatment options • Lifestyle • Diet, exercise • Insulin • Islet transplantation

  8. Type 1 diabetes Premixed Insulin Basal Bolus Regime

  9. Diagrammatic representation of physiological insulin secretion and 30/70 pre-mixed insulin time-action profile Physiological insulin Pre-mixed 30/70 regimen Blood insulin levels 24.00 06.00 18.00 06.00 12.00 Breakfast Lunch Dinner Why pre-mixed insulins don’t work

  10. Type 2 diabetes - treatment options

  11. Type 2 diabetes - treatment options • Lifestyle • Diet, exercise • Oral monotherapy • Oral combination therapy • Insulin (with or without oral agents)

  12. -glucosidase inhibitors Carbohydrate Sulphonylureas Incretin mimetics DPP-IV inhibitors Insulin acts on all tissues Biguanides Primary sites of action of hypoglycaemic agents Stomach Gut I Glucose G I Adipose tissue I G Insulin G G I G I Pancreas G I G I G I G I G Muscle I G G Thiazolidinediones Liver Adapted from Kobayashi M. Diabetes Obes Metab 1999; 1 (Suppl. 1):S32–S40.Nattrass M & Bailey CJ. Baillieres Best Pract Res Clin Endocrinol Metab 1999; 13:309–329.

  13. Oral hypoglycaemic agents

  14. Oral hypoglycaemic agents • Metformin • Sulphonylureas • Acarbose • Guar gum • Postprandial glucose regulators • Thiazolidinediones • Dipeptidyl peptidase-IV inhibitors By injection • Incretin mimetics

  15. Metformin : history • French Lilac or Goat’s Rue (Galega officianalis) - a traditional remedy for diabetes - is rich in guanidine

  16. Metformin : history • Used by mediaeval monks • 1920s : guanidine derivatives introduced, then forgotten • 1957 : metformin, phenformin • 1970s : phenformin withdrawn • 1994 : metformin obtained FDA approval in USA

  17. Metformin : efficacy •  FPG 2 - 4,  HbA1c 1 - 2% • Effect depends on the presence of insulin • Hypoglycaemia unlikely with monotherapy • Weight neutral • Small improvement in lipid profile • Reduced cardiovascular events

  18. UKPDS : metformin in over- weight subjects Myocardial infarction Diabetes-related endpoints All-cause mortality Diabetes-related deaths 0 5 10 15 20 Risk reduction (%) 25 30 35 p = 0.0023 p = 0.011 40 p = 0.01 45 p = 0.017 p values in comparison to conventional treatment group United Kingdom Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854–865.

  19. Metformin : use • First – line monotherapy in obese and non-obese • Combination with other oral agents : effects additive • Combination with insulin

  20. Metformin : contraindications

  21. Metformin : contraindications • Impaired renal function • Cardiac or respiratory insufficiency • Liver disease, alcohol abuse • History of metabolic acidosis • Severe sepsis • Use of IV contrast media

  22. Metformin : adverse effects

  23. Metformin : adverse effects • Lactic acidosis: • 0.03 cases / 1000 patient years • 50% mortality • GI symptoms • B12 malabsorption

  24. Sulphonylureas : history • 1940s : sulphonamides noted to cause hypoglycaemia. • 1950s : carbutamide, tolbutamide • 1960s : tolazamide, chlorpropamide • 1970s : ? detrimental cardiovascular effects • 1970s – 1980s : glibenclamide, glipizide, gliclazide • 1990s : glimepiride

  25. Sulphonylureas : efficacy •  FPG 2 - 4,  HbA1c 1 - 2% • Only effective if beta-cell still functioning. • Can initiate insulin release when plasma glucose < 5. • Maximum glucose lowering effect may be achieved below maximum permitted dose.

  26. Sulphonylureas : use • Not preferred in obese subjects • Monotherapy • Combination with other oral agents : effects additive • ? Combination with insulin

  27. Sulphonylureas : adverse effects

  28. Sulphonylureas : adverse effects • Hypoglycaemia • Weight gain : 1 - 4 KGm in 6 months • Sensitivity reactions

  29. Postprandial glucose regulators • Nateglinide, repaglinide • Reduce postprandial glucose spikes by restoring early phase insulin release • Reduce HbA1c% by 0.5-2.0% • Main use in combination with metformin • Meal time flexibility • ? Less weight gain than with sulphonylureas • Gastrointestinal side-effects, hypoglycaemia • No outcome data

  30. Glitazones : history • 1980s : effect first described • 1997 : troglitazone introduced – and withdrawn • 1999 : rosiglitazone (Avandia  , GSK) and pioglitazone (Actos  , Takeda) introduced. • 2005 : PROactive Study – small reduction in CV events with pioglitazone. • 2007 : does rosiglitazone increase CV events?

  31. Glitazones : efficacy •  FPG 2 - 3,  HbA1c around 1 % • Effect depends on the presence of insulin • Full expression of dose may not be apparent for 3 months • Not all patients respond

  32. Glitazones : adverse effects

  33. Glitazones : adverse effects • Fluid retention : oedema , heart failure , anaemia • Weight gain : 1 – 4 KGm in 6 months • Hypoglycaemia in combination with other oral agents • ? Unforeseen chronic effects

  34. Glitazones : contraindications

  35. Glitazones : contraindications • Heart failure • Oedema • Anaemia • ? Insulin therapy • ? Impaired liver function

  36. New agents for T2D • CB1 receptor antagonist • Rimonabant • Glucagon-like peptide-1 (GLP-1) receptor agonists (incretin mimetics) • Exenatide • Liraglutide • Dipeptidyl peptidase-4 (DPP-4) inhibitors (incretin enhancers) • Sitagliptin • Vildagliptin

  37. UKPDS : glycaemic control

  38. UKPDS : decline of -cell function over time 100 100 Start of treatment 80 80 60 60 -cell function (%) 40 40 20 0 –10 –9 –8 –7 –6 –5 –4 –3 –2 –1 1 2 3 4 5 6 Time from diagnosis (years) HOMA model, diet-treatedn = 376 Adapted from Holman RR. Diabetes Res Clin Pract 1998; 40 (Suppl.):S21–S25.

  39. Insulin : history • 1921 : Banting and Best • 1940s : protamine and zinc • 1980s : human insulin • 1990s : insulin analogues

  40. Insulin : mechanisms • Reduces : • Glycogen breakdown • Gluconeogenesis • Lipolysis • Protein breakdown Increases : • Glucose uptake by cells • Glycogen synthesis • Fatty acid synthesis • Cholesterol & LDL synthesis • Amino acid transport • Protein synthesis

  41. Insulin : use

  42. Insulin : use • Type 1 diabetes • Improved metabolic control in type 2 diabetes • Oral therapies contraindicated or not tolerated • Post-myocardial infarction (DIGAMI) • Severe intercurrent illness , surgery • Gestational diabetes not controlled by diet

  43. Insulin : adverse effects

  44. Insulin : adverse effects • Hypoglycaemia • Weight gain • Allergy • Lipohypertrophy and lipoatrophy • Transient deterioration of retinopathy • Insulin neuritis

  45. Control versus hypos : DCCT

  46. 10.0 7.5 Intensive (Insulin) 5.0 Change in weight (kg) 2.5 Conventional 0 0 3 6 9 12 15 Years from randomisation Weight gain with insulin : UKPDS

  47. Insulin preparations Short acting onset 30 mins Humulin S peak 2-4 hours Actrapid duration 8 hours Intermediate onset 1-2 hours Insulatard peak 4-12 hours Humulin I duration 16-24 hours Long acting onset 1-2 hours Human Ultratard peak 4-12 hours Humulin Zn duration 20-35 hours Analogue onset 0-15mins Humalog (Lispro) peak 1-2 hours Novorapid (Aspart) duration 4-6 hours duration 24 hours Glargine , Levemir

  48. How many do you need ?

  49. How many do you need ? • Novorapid • NPH • Glargine • Detemir • Novomix 30

More Related